TapewireFind a company

person · Reporting owner

Dickinson Andrew D

Disclosed activity across 1 company

Tapewire entity
14295
SEC CIK
0001310204

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
GILEAD SCIENCES, INC.GILD · Entity 405Chief Financial OfficerSeptember 15, 2026September 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GILEAD SCIENCES, INC.

Report date September 15, 2026 · Filed September 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect164,096 Reported balance After 2026-09-15 transaction · row 1
1 source row

Row 1 · 2026-09-15 · Sale · Disposed 3,000 · Balance 164,096

F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 10, 2025 Filed Mar 12, 2025 22:41 UTC GILEAD SCIENCES, INC. GILD · Entity 405 SaleCommon Stock 4,916 $117.30 $576,640.90
Disclosure

SEC source: 0001127602-25-009283 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 182,074

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F2 · price: Sale prices reported for the transactions reported here range from $116.97 to $117.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 22:41 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 13,013 $63.91 $831,660.83
Disclosure

SEC source: 0001127602-25-009283 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 186,990

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 22:41 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 4,916 $63.91 $314,181.56
Disclosure

SEC source: 0001127602-25-009283 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,977

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
February 18, 2025 Filed Feb 19, 2025 21:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 SaleCommon Stock 2,500 $104.09 $260,225.00
Disclosure

SEC source: 0001127602-25-005525 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 169,061

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F2 · balance_after: Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 02:13 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 18,210 $0.00 Strike: $83.49 $0.00
Disclosure

SEC source: 0001127602-25-004784 · form4.xml · derivative · entry 9

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,210 shares

Expires 2028-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 02:13 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 15,600 $0.00 Strike: $80.72 $0.00
Disclosure

SEC source: 0001127602-25-004784 · form4.xml · derivative · entry 8

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,600 shares

Expires 2028-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 02:13 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 26,175 $0.00 Strike: $57.92 $0.00
Disclosure

SEC source: 0001127602-25-004784 · form4.xml · derivative · entry 7

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,515

Underlying: Common Stock · 26,175 shares

Expires 2032-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 02:13 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 77,691 $0.00 Strike: $63.91 $0.00
Disclosure

SEC source: 0001127602-25-004784 · form4.xml · derivative · entry 6

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,929

Underlying: Common Stock · 77,691 shares

Expires 2031-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F2 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 02:13 UTC GILEAD SCIENCES, INC. GILD · Entity 405 SaleCommon Stock 137,676 $102.22 $14,073,240.72
Disclosure

SEC source: 0001127602-25-004784 · form4.xml · nonDerivative · entry 5

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,223

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 02:13 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 18,210 $83.49 $1,520,352.90
Disclosure

SEC source: 0001127602-25-004784 · form4.xml · nonDerivative · entry 4

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 308,899

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 02:13 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 15,600 $80.72 $1,259,232.00
Disclosure

SEC source: 0001127602-25-004784 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 290,689

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 02:13 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 26,175 $57.92 $1,516,056.00
Disclosure

SEC source: 0001127602-25-004784 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 275,089

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 02:13 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 77,691 $63.91 $4,965,231.81
Disclosure

SEC source: 0001127602-25-004784 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 248,914

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:11 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 43,138 $97.99 $4,227,092.62
Disclosure

SEC source: 0001127602-25-003362 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,223

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:11 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantCommon Stock 64,695 $0.00 $0.00
Disclosure

SEC source: 0001127602-25-003362 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 214,361

F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on March 10, 2022. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:11 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantCommon Stock 19,793 $0.00 $0.00
Disclosure

SEC source: 0001127602-25-003362 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,666

F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2023 and March 10, 2024. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until the requisite continuing service requirements are also met.

Read SEC document
January 31, 2025 Filed Feb 3, 2025 23:09 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 44,160 $0.00 Strike: $65.38 $0.00
Disclosure

SEC source: 0001127602-25-002821 · form4.xml · derivative · entry 7

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,160 shares

Expires 2029-11-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F3 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
January 31, 2025 Filed Feb 3, 2025 23:09 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 71,850 $0.00 Strike: $72.34 $0.00
Disclosure

SEC source: 0001127602-25-002821 · form4.xml · derivative · entry 6

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 71,850 shares

Expires 2030-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F3 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
January 31, 2025 Filed Feb 3, 2025 23:09 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 26,170 $0.00 Strike: $57.92 $0.00
Disclosure

SEC source: 0001127602-25-002821 · form4.xml · derivative · entry 5

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,690

Underlying: Common Stock · 26,170 shares

Expires 2032-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F3 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
January 31, 2025 Filed Feb 3, 2025 23:09 UTC GILEAD SCIENCES, INC. GILD · Entity 405 SaleCommon Stock 142,180 $97.22 $13,822,739.60
Disclosure

SEC source: 0001127602-25-002821 · form4.xml · nonDerivative · entry 4

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,873

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F2 · price: Sales prices reported for the transactions reported here range from $97.22 to $97.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

Read SEC document
January 31, 2025 Filed Feb 3, 2025 23:09 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 44,160 $65.38 $2,887,180.80
Disclosure

SEC source: 0001127602-25-002821 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 273,053

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
January 31, 2025 Filed Feb 3, 2025 23:09 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 71,850 $72.34 $5,197,629.00
Disclosure

SEC source: 0001127602-25-002821 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 227,893

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
January 31, 2025 Filed Feb 3, 2025 23:09 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 26,170 $57.92 $1,515,766.40
Disclosure

SEC source: 0001127602-25-002821 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,043

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
January 15, 2025 Filed Jan 16, 2025 20:31 UTC GILEAD SCIENCES, INC. GILD · Entity 405 SaleCommon Stock 2,500 $91.35 $228,375.00
Disclosure

SEC source: 0001127602-25-001321 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,873

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
December 16, 2024 Filed Dec 17, 2024 22:27 UTC GILEAD SCIENCES, INC. GILD · Entity 405 SaleCommon Stock 8,500 $91.96 $781,660.00
Disclosure

SEC source: 0001127602-24-029638 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 132,373

F1 · kind: The transaction reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
December 10, 2024 Filed Dec 12, 2024 00:05 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 3,640 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-24-029165 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,487

Underlying: Common Stock · 3,640 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
December 10, 2024 Filed Dec 12, 2024 00:05 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 1,686 $92.34 $155,685.24
Disclosure

SEC source: 0001127602-24-029165 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,873

Read SEC document
December 10, 2024 Filed Dec 12, 2024 00:05 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 3,640 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-24-029165 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 65,960 $0.00 Strike: $72.70 $0.00
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · derivative · entry 14

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,960 shares

Expires 2026-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F4 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 43,340 $0.00 Strike: $72.70 $0.00
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · derivative · entry 13

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 43,340 shares

Expires 2027-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F5 · derivative.exercise_date: The shares subject to the option have a three year vesting schedule. 33.33% vest on the first anniversary of the date of the grant. The balance will vest 8.33% quarterly thereafter until fully vested.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 60,885 $0.00 Strike: $71.91 $0.00
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · derivative · entry 12

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,885 shares

Expires 2028-06-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F4 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 33,660 $0.00 Strike: $68.75 $0.00
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · derivative · entry 11

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,660 shares

Expires 2029-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F4 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 18,630 $0.00 Strike: $73.77 $0.00
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · derivative · entry 10

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,630 shares

Expires 2027-11-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F5 · derivative.exercise_date: The shares subject to the option have a three year vesting schedule. 33.33% vest on the first anniversary of the date of the grant. The balance will vest 8.33% quarterly thereafter until fully vested.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 26,170 $0.00 Strike: $57.92 $0.00
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · derivative · entry 9

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,860

Underlying: Common Stock · 26,170 shares

Expires 2032-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F4 · derivative.exercise_date: The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 SaleCommon Stock 127,930 $92.76 $11,867,119.42
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 8

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 138,919

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F3 · price: Sales prices reported for the transactions reported here range from $92.33 to $93.09. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 SaleCommon Stock 120,715 $92.77 $11,198,151.12
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 7

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 266,849

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

F2 · price: Sales prices reported for the transactions reported here range from $92.36 to $93.09. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 65,960 $72.70 $4,795,292.00
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 6

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 387,564

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 43,340 $72.70 $3,150,818.00
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 5

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 321,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 60,885 $71.91 $4,378,240.35
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 4

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 278,264

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 33,660 $68.75 $2,314,125.00
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 217,379

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 26,170 $57.92 $1,515,766.40
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,719

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
November 29, 2024 Filed Dec 3, 2024 19:43 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 18,630 $73.77 $1,374,335.10
Disclosure

SEC source: 0001127602-24-028397 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 157,549

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Read SEC document
September 10, 2024 Filed Sep 11, 2024 23:20 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 3,641 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-24-023815 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,127

Underlying: Common Stock · 3,641 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
September 10, 2024 Filed Sep 11, 2024 23:20 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 1,682 $81.44 $136,982.08
Disclosure

SEC source: 0001127602-24-023815 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,919

Read SEC document
September 10, 2024 Filed Sep 11, 2024 23:20 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 3,641 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-24-023815 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,601

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Read SEC document
June 10, 2024 Filed Jun 11, 2024 23:25 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionRestricted Stock Unit · Derivative 3,639 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-24-018421 · form4.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,768

Underlying: Common Stock · 3,639 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
June 10, 2024 Filed Jun 11, 2024 23:25 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Tax withholdingCommon Stock 1,662 $65.25 $108,445.50
Disclosure

SEC source: 0001127602-24-018421 · form4.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,960

Read SEC document
June 10, 2024 Filed Jun 11, 2024 23:25 UTC GILEAD SCIENCES, INC. GILD · Entity 405 Exercise / conversionCommon Stock 3,639 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-24-018421 · form4.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,622

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Read SEC document
March 10, 2024 Filed Mar 12, 2024 00:59 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantRestricted Stock Unit · Derivative 17,305 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-24-009540 · form4.xml · derivative · entry 7

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,407

Underlying: Common Stock · 17,305 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F4 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F4 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document
March 10, 2024 Filed Mar 12, 2024 00:59 UTC GILEAD SCIENCES, INC. GILD · Entity 405 GrantNon-qualified Stock Option (Right to Buy) · Derivative 87,970 $0.00 Strike: $75.12 $0.00
Disclosure

SEC source: 0001127602-24-009540 · form4.xml · derivative · entry 6

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,970

Underlying: Common Stock · 87,970 shares

Expires 2034-03-10

F5 · derivative.exercise_date: The options have a four year vesting schedule. 25% vest on the first anniversary date of the date grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.